Læknaneminn - 01.04.2018, Blaðsíða 138

R
an
ns
ók
na
rv
er
ke
fn
i 3
. á
rs
n
em
a
20
17
13
8
61. Lim D, Oliva E. Precursors and pathogenesis
of ovarian carcinoma. Pathology. Apr
2013;45(3):229­242.
62. Meinhold­Heerlein I, Fotopoulou C, Harter P,
et al. The new WHO classification of ovarian,
fallopian tube, and primary peritoneal cancer
and its clinical implications. Arch. Gynecol.
Obstet. Apr 2016;293(4):695­700.
63. Prat J, Ribe A, Gallardo A. Hereditary ovarian
cancer. Hum. Pathol. Aug 2005;36(8):861­870.
64. Russo A, Calo V, Bruno L, Rizzo S, Bazan V,
Di Fede G. Hereditary ovarian cancer. Crit.
Rev. Oncol. Hematol. Jan 2009;69(1):28­44.
65. Ford D, Easton DF, Stratton M, et al. Genetic
heterogeneity and penetrance analysis of
the BRCA1 and BRCA2 genes in breast
cancer families. The Breast Cancer Linkage
Consortium. Am. J. Hum. Genet. Mar
1998;62(3):676­689.
66. Jelovac D, Armstrong DK. Recent progress in
the diagnosis and treatment of ovarian cancer.
CA Cancer J. Clin. May­Jun 2011;61(3):183­
203.
67. Salehi F, Dunfield L, Phillips KP, Krewski
D, Vanderhyden BC. Risk factors for ovarian
cancer: an overview with emphasis on
hormonal factors. J. Toxicol. Environ. Health. B
Crit. Rev. Mar 2008;11(3­4):301­321.
68. Iversen L, Sivasubramaniam S, Lee AJ,
Fielding S, Hannaford PC. Lifetime cancer
risk and combined oral contraceptives: the
Royal College of General Practitioners’ Oral
Contraception Study. Am. J. Obstet. Gynecol.
Jun 2017;216(6):580.e581­580.e589.
69. La Vecchia C. Ovarian cancer: epidemiology
and risk factors. Eur. J. Cancer Prev. Jan 1 2016.
70. Quirk JT, Natarajan N. Ovarian cancer
incidence in the United States, 1992­1999.
Gynecol. Oncol. May 2005;97(2):519­523.
71. Rendi MH. Epithelial carcinoma of the
ovary, fallopian tube, and peritoneum:
Histopathology. 2015; http://www.uptodate.
com/contents/epithelial­carcinoma­of­
the­ovary­fallopian­tube­and­peritoneum­
histopathology. Accessed 3/30 2016, 2016.
72. Kobel M, Kalloger SE, Huntsman DG, et al.
Differences in tumor type in low­stage versus
high­stage ovarian carcinomas. Int. J. Gynecol.
Pathol. May 2010;29(3):203­211.
73. Heintz AP, Odicino F, Maisonneuve P, et al.
Carcinoma of the ovary. FIGO 26th Annual
Report on the Results of Treatment in
Gynecological Cancer. Int. J. Gynaecol. Obstet.
Nov 2006;95 Suppl 1:S161­192.
74. Akeson M, Jakobsen AM, Zetterqvist BM,
Holmberg E, Brannstrom M, Horvath G.
A population­based 5­year cohort study
including all cases of epithelial ovarian cancer
in western Sweden: 10­year survival and
prognostic factors. Int. J. Gynecol. Cancer. Jan
2009;19(1):116­123.
75. Prat J. Ovarian carcinomas: five distinct
diseases with different origins, genetic
alterations, and clinicopathological features.
Virchows Arch. Mar 2012;460(3):237­249.
76. Fleming GF, Ronett BM, Seidman J, Zaino
RJ, Rubin SC. Principles and Practice of
Gyneologic Oncology. Epithelial Ovarian Cancer.
5 ed. Baltimore: Lippincott Williams &
Wilkins, a Wolters Kluwer business; 2009.
77. Jones MB. Borderline ovarian tumors: current
concepts for prognostic factors and clinical
management. Clin. Obstet. Gynecol. Sep
2006;49(3):517­525.
78. Ebell MH, Culp MB, Radke TJ. A Systematic
Review of Symptoms for the Diagnosis
of Ovarian Cancer. Am. J. Prev. Med. Mar
2016;50(3):384­394.
79. Goff BA. Early detection of epithelial ovarian
cancer: Role of symptom recognition. 2014;
http://www.uptodate.com/contents/early­
detection­of­epithelial­ovarian­cancer­role­
of­symptom­recognition?source=see_link.
Accessed 11. apríl, 2016.
80. Engelholm SA, Havsteen H, Lund B, et
al. Retningslinier for visitation, diagnostik og
kontrol af epitelial ovarie-, tuba- og primær
peritonealcancer samt borderline tumorer. 4 ed:
Dansk Gynækologisk Cancer Gruppe; 2012.
81. Bottoni P, Scatena R. The Role of CA 125
as Tumor Marker: Biochemical and Clinical
Aspects. Adv. Exp. Med. Biol. 2015;867:229­
244.
82. Buys SS, Partridge E, Black A, et al.
Effect of screening on ovarian cancer
mortality: the Prostate, Lung, Colorectal
and Ovarian (PLCO) Cancer Screening
Randomized Controlled Trial. JAMA. Jun 8
2011;305(22):2295­2303.
83. Kurman RJ, Shih I­M. Molecular pathogenesis
and extraovarian origin of epithelial ovarian
cancer—Shifting the paradigm. Hum. Pathol.
7// 2011;42(7):918­931.
84. Prat J, FIGO committee on Gynecologic
Oncology. Staging classification for cancer
of the ovary, fallopian tube, and peritoneum.
International Journal of Gynecology & Obstetrics.
1// 2014;124(1):1­5.
85. Kalapotharakos G, Hogberg T, Bergfeldt K,
Borgfeldt C. Long­term survival in women
with borderline ovarian tumors: a population­
based survey of borderline ovarian tumors in
Sweden 1960­2007. Acta Obstet. Gynecol. Scand.
2016 Apr (Epub 2016 Jan 2016;95(4):473­
479.
86. Hoskins WJ. Epithelial ovarian carcinoma:
principles of primary surgery. Gynecol. Oncol.
Dec 1994;55(3 Pt 2):S91­96.
87. Mann WJ, Chalas E, Valea FA. Cancer of
the ovary, fallopian tube, and peritoneum:
Staging and initial surgical management.
UpToDate 2014; http://www.uptodate.com/
contents/cancer­of­the­ovary­fallopian­tube­
and­peritoneum­staging­and­initial­surgical­
management. Accessed 21.4, 2016.
88. Gallotta V, Petrillo M, Conte C, et al.
Laparoscopic Versus Laparotomic Surgical
Staging for Early­Stage Ovarian Cancer:
A Case­Control Study. J. Minim. Invasive
Gynecol. Mar 16 2016.
89. Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL, Montz FJ. Survival effect of
maximal cytoreductive surgery for advanced
ovarian carcinoma during the platinum
era: a meta­analysis. J. Clin. Oncol. Mar 1
2002;20(5):1248­1259.
90. Chi DS, Eisenhauer EL, Lang J, et al. What
is the optimal goal of primary cytoreductive
surgery for bulky stage IIIC epithelial ovarian
carcinoma (EOC)? Gynecol. Oncol. Nov
2006;103(2):559­564.
91. Eisenkop SM, Spirtos NM, Friedman RL,
Lin WC, Pisani AL, Perticucci S. Relative
influences of tumor volume before surgery
and the cytoreductive outcome on survival
for patients with advanced ovarian cancer:
a prospective study. Gynecol. Oncol. Aug
2003;90(2):390­396.
92. Peiretti M, Zanagnolo V, Aletti GD, et al.
Role of maximal primary cytoreductive surgery
in patients with advanced epithelial ovarian
and tubal cancer: Surgical and oncological
outcomes. Single institution experience.
Gynecol. Oncol. Nov 2010;119(2):259­264.
93. Herzog TJ, Armstrong DK. First­line
chemotherapy for advanced (stage III or
IV) epithelial ovarian, fallopian tubal, and
peritoneal cancer. UpToDate 2016; 66:http://
www.uptodate.com/contents/first­line­
chemotherapy­for­advanced­stage­iii­or­
iv­epithelial­ovarian­fallopian­tubal­and­
peritoneal­cancer Accessed 22.4, 2016.
94. Raja FA, Chopra N, Ledermann JA. Optimal
first­line treatment in ovarian cancer. Ann.
Oncol. Sep 2012;23 Suppl 10:x118­127.
95. Bell J, Brady MF, Young RC, et al.
Randomized phase III trial of three versus six
cycles of adjuvant carboplatin and paclitaxel
in early stage epithelial ovarian carcinoma: a
Gynecologic Oncology Group study. Gynecol.
Oncol. Sep 2006;102(3):432­439.
96. Thrall MM, Gray HJ, Symons RG, Weiss
NS, Flum DR, Goff BA. Neoadjuvant
chemotherapy in the Medicare cohort with
advanced ovarian cancer. Gynecol. Oncol. Dec
2011;123(3):461­466.
97. Konstantinopoulos PA, Bristow RE.
Neoadjuvant chemotherapy for newly
diagnosed advanced ovarian cancer. UpToDate
2014; http://www.uptodate.com/contents/
neoadjuvant­chemotherapy­for­newly­
diagnosed­advanced­ovarian­cancer. Accessed
22.4., 2016.
98. Perren TJ, Swart AM, Pfisterer J, et al. A
Phase 3 Trial of Bevacizumab in Ovarian
Cancer. N. Engl. J. Med. 2011;365(26):2484­
2496.
99. Burger RA, Brady MF, Bookman MA, et al.
Incorporation of bevacizumab in the primary
treatment of ovarian cancer. N. Engl. J. Med.
Dec 29 2011;365(26):2473­2483.
100. Oza AM, Cook AD, Pfisterer J, et al. Standard
chemotherapy with or without bevacizumab
for women with newly diagnosed ovarian
cancer (ICON7): overall survival results of a
phase 3 randomised trial. Lancet Oncol. Aug
2015;16(8):928­936.
101. Parkes EE, Kennedy RD. Clinical Application
of Poly(ADP­Ribose) Polymerase Inhibitors
in High­Grade Serous Ovarian Cancer.
Oncologist. Mar 28 2016.
102. Cortesi L, Toss A, Cucinotto I. Parp Inhibitors
for the Treatment of Ovarian Cancer. Curr.
Cancer Drug Targets. Mar 7 2018.
103. Tummala MK, McGuire WP. Recurrent
ovarian cancer. Clin. Adv. Hematol. Oncol. Sep
2005;3(9):723­736.
104. Winter WE, 3rd, Maxwell GL, Tian C, et
al. Prognostic factors for stage III epithelial
ovarian cancer: a Gynecologic Oncology
Group Study. J. Clin. Oncol. Aug 20
2007;25(24):3621­3627.
105. Barnhill DR, Kurman RJ, Brady MF, et al.
Preliminary analysis of the behavior of stage
I ovarian serous tumors of low malignant
potential: a Gynecologic Oncology Group
study. J. Clin. Oncol. Nov 1995;13(11):2752­
2756.